Relevance of aneuploidy for cancer therapies targeting the spindle assembly checkpoint and KIF18A

Yael Cohen-Sharir; Uri Ben-David

doi:10.1080/23723556.2021.1915075

Relevance of aneuploidy for cancer therapies targeting the spindle assembly checkpoint and KIF18A

Mol Cell Oncol. 2021 Apr 25;8(3):1915075. doi: 10.1080/23723556.2021.1915075. eCollection 2021.

Authors

Yael Cohen-Sharir¹, Uri Ben-David¹

Affiliation

¹ Department of Human Molecular Genetics & Biochemistry, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Abstract

Aneuploidy, a common feature of cancer cells, results in increased sensitivity to the inhibition of the spindle assembly checkpoint (SAC) and the mitotic motor protein Kinesin Family Member 18A (KIF18A). We discuss the importance of drugs targeting SAC core members and KIF18A. We stress the need to assess the sensitivity to this class of drugs at appropriate time points, and propose that aneuploidy could serve as a biomarker to stratify patients for SAC-targeting treatments.

Keywords: Aneuploidy; KIF18A; SAC; cancer; cancer therapies; spindle assembly checkpoint.

Grants and funding

This work was supported by the Azrieli Foundation, the Richard Eimert Research Fund on Solid Tumors, the Tel-Aviv University Cancer Biology Research Center, the Israel Cancer Association (20200111 to U.B.-D.), the Israel Cancer Research Fund (Gesher Award to U.B.-D.), and the DoD CDMRP career development award (CA191148 to U.B.-D.).